In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses

被引：0
|
作者：
Le Hingrat, Q. [1 ]
Collin, G. [1 ]
Damond, F. [1 ]
Peytavin, G. [2 ]
Lebourgeois, S. [1 ]
Ghosn, J. [3 ]
Bachelard, A. [3 ]
Ferre, V. [1 ]
Matheron, S. [3 ]
Descamps, D. [1 ]
Charpentier, C. [1 ]
机构：
[1] Hop Bichat Claude Bernard, AP HP, Lab Virol, Paris, France
[2] Hop Bichat Claude Bernard, AP HP, Lab Pharmacol, Paris, France
[3] Hop Bichat Claude Bernard, AP HP, Serv Malad Infect & Trop, Paris, France
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
E13/27
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions
    Le Hingrat, Quentin
    Collin, Gilles
    Damond, Florence
    Peytavin, Gilles
    Lebourgeois, Samuel
    Ghosn, Jade
    Bachelard, Antoine
    Ferre, Valentine Marie
    Matheron, Sophie
    Descamps, Diane
    Charpentier, Charlotte
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (02) : 409 - 412
  • [2] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, Ct
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S92 - S92
  • [3] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, G.
    Bernard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamp, D.
    ANTIVIRAL THERAPY, 2007, 12 : S92 - S92
  • [4] HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Peytavin, G.
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 914 - 920
  • [5] In vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
    Charpentier, C.
    Damond, F.
    Collin, G.
    Larrouy, L.
    Matheron, S.
    Chene, G.
    Roquebert, B.
    Nie, T.
    Schinazi, R. F.
    Brun-Vezinet, F.
    Descamps, D.
    ANTIVIRAL THERAPY, 2010, 15 : A58 - A58
  • [6] In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
    Charpentier, Charlotte
    Larrouy, Lucile
    Collin, Gilles
    Damond, Florence
    Matheron, Sophie
    Chene, Genevieve
    Nie, Ting
    Schinazi, Raymond
    Brun-Vezinet, Francoise
    Descamps, Diane
    AIDS, 2010, 24 (17) : 2753 - 2755
  • [7] Phenotypic susceptibility of HIV-2 clinical isolates to maraviroc
    Visseaux, B.
    Hurtado-Nedelec, M.
    Charpentier, C.
    Antoine, R.
    Storto, A.
    Matheron, S.
    Larrouy, L.
    Damond, F.
    Brun-Vezinet, F.
    Descamps, D.
    ANTIVIRAL THERAPY, 2011, 16 : A48 - A48
  • [8] In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors
    Visseaux, Benoit
    Charpentier, Charlotte
    Hurtado-Nedelec, Margarita
    Storto, Alexandre
    Antoine, Romain
    Peytavin, Gilles
    Damond, Florence
    Matheron, Sophie
    Brun-Vezinet, Francoise
    Descamps, Diane
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 137 - 139
  • [9] REPLICATIVE CAPACITY OF HIV-2, LIKE HIV-1, CORRELATES WITH SEVERITY OF IMMUNODEFICIENCY
    ALBERT, J
    NAUCLER, A
    BOTTIGER, B
    BROLIDEN, PA
    ALBINO, P
    OUATTARA, SA
    BJORKEGREN, C
    VALENTIN, A
    BIBERFELD, G
    FENYO, EM
    AIDS, 1990, 4 (04) : 291 - 295
  • [10] In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors:: Amprenavir, atazanavir, lopinavir, and tipranavir
    Descamps, D.
    Desbois, D.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, G.
    Bénard, A.
    Campa, P.
    Chêne, G.
    Brun-Vézinet, F.
    ANTIVIRAL THERAPY, 2006, 11 (05) : S103 - S103
12345